Skip to Main Content

Paper Details

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Blood Cancer J
6
2023
Author NameAffiliation
Gautam BorthakurMD Anderson Cancer Center
Steven M KornblauMD Anderson Cancer Center
Guillermo Garcia-ManeroMD Anderson Cancer Center
Farhad RavandiMD Anderson Cancer Center
Hagop KantarjianMD Anderson Cancer Center
Courtney D DiNardoMD Anderson Cancer Center
  • 1 - 6

Datasets

Release 1.2